Document Detail


Endograft salvage of hemodialysis accesses threatened by pseudoaneurysms.
MedLine Citation:
PMID:  23036977     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Currently, no formal practice guidelines exist regarding the use of endografts to exclude hemodialysis access pseudoaneurysms and prolong access lifespan in dialysis patients. We evaluated the efficacy of percutaneous endograft placement for exclusion of hemodialysis access pseudoaneurysms. METHODS: Between July 2005 and October 2009, 32 patients were prospectively evaluated. Twenty-four patients were actively enrolled in the study based upon clinical and ultrasonographic evaluation of their hemodialysis accesses. Self-expanding covered endografts were placed percutaneously to exclude access pseudoaneurysms. Patients were evaluated at 2 and 6 months to assess for graft patency, access or outflow stenosis, endoleak, or stent graft migration. RESULTS: No procedural complications resulted from these interventions. An average of 1.8 endografts was placed per patient, with patients requiring between 1 and 3 endografts to exclude pseudoaneurysms. Primary-assisted patency was 83% at completed 2-month follow-up and 54% at 6-month follow-up. At 12 months, primary-assisted patency was 50%. Eleven patients left the study before 6-month follow-up: five (21%) required explantation secondary to infection between 1 and 4 months; three (13%) were lost to follow-up; two (8%) died of unrelated causes; and 1 requested explantation citing pain from the "stent poking the vein." Mean time to explantation secondary to infection was 2.4 months. Mean duration of patency was 17.6 months with a range from 0 to 76 months. Mean duration of patency for patients who completed 6-month follow-up was 28.7 months. The longest duration of patency is 6 years 4 months, after stent fracture and subsequent placement of a new stent at 6 years 2 months. One other incident of stent fracture occurred at 36 months. Dialysis patterns were not interrupted in either patient. CONCLUSIONS: The long-term results demonstrate that endograft salvage of failing hemodialysis accesses is a viable and safe alternative to open surgical revision that excludes pseudoaneurysms while maintaining uninterrupted access patency. A larger sample size and longer follow-up are needed to support the study data.
Authors:
Alison J Kinning; Russell W Becker; Gregory J Fortin; Robert G Molnar; Carlo A Dall'olmo
Related Documents :
18576337 - Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographica...
23252547 - Relapse risk after discontinuation of risperidone in alzheimer's disease.
23462067 - Percutaneous interventions on the hemodialysis reliable outflow vascular access device.
10524687 - The prosorba column for treatment of refractory rheumatoid arthritis: a randomized, dou...
16998677 - Long-term results of microscopic lymphatic vessel-isolated vein anastomosis for seconda...
20825837 - Pretest probability estimation in the evaluation of patients with possible deep vein th...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-1
Journal Detail:
Title:  Journal of vascular surgery     Volume:  -     ISSN:  1097-6809     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Mosby, Inc. All rights reserved.
Affiliation:
American University of the Caribbean School of Medicine, Sint Maarten. Electronic address: akinning@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reinvestigation of Structures of Robustasides B and C, and Isolation of (E)-2,5-Dihydroxycinnamic Ac...
Next Document:  Lysophosphatidic acid induces increased BACE1 expression and A? formation.